Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
hopeful2bright
hopeful2bright Dec. 5 at 12:24 AM
$ABUS
0 · Reply
Iightning
Iightning Dec. 4 at 11:17 PM
1ightning® Premium Options Alert (Actionable) Ticker: $ABUS Contract: Dec 19 $4C Entry: 0.47 Exit: 0.67 Return: +40.94% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 10:38 PM
Enter: $ABUS Calls Strike Price: $4 Expiry Date: JAN 16 2026 Buy in Price: $0.55 - $1.09 Sell Price: $1.85 Profit : +70% (Turn every $1 into $1.70) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Alfalcon
Alfalcon Dec. 4 at 10:20 PM
$ABUS ready to demote this slug to wagon status.
1 · Reply
FatedFish
FatedFish Dec. 4 at 9:06 PM
$ABUS
0 · Reply
NoBSPls
NoBSPls Dec. 4 at 7:30 PM
$ABUS I see 3 potential catalysts in the cards. 1. News on the pipeline. 2. B/O news 3. Progress on patent cases. Any/all could hit soon. This one requires steel nerves and a lot of patience. Another multi year journey for me 😊
1 · Reply
Blueviking
Blueviking Dec. 4 at 7:26 PM
$ABUS Been a cracy ass bus Wayne, what a ride🥳
0 · Reply
J_Wayne
J_Wayne Dec. 4 at 6:27 PM
$ABUS give me 10, 15, 20. Whatever….just want to get off the bus 😅
6 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 2:44 PM
$ABUS Share Price: $4.39 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.02 – $2.46 Potential Upside: 66% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
renoH4
renoH4 Dec. 4 at 1:24 PM
$ABUS ..adding, we are not far away of mother news.
1 · Reply
Latest News on ABUS
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 21 days ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Arbutus (ABUS) Q2 Revenue Surges 529%

Aug 6, 2025, 2:48 PM EDT - 4 months ago

Arbutus (ABUS) Q2 Revenue Surges 529%

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:30 AM EDT - 4 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 5 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 7 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 7 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 8 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 9 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 9 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 9 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 10 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Jan 30, 2025, 3:40 PM EST - 11 months ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 11 months ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jan 7, 2025, 7:56 AM EST - 11 months ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 2:52 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:05 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 1 year ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

hopeful2bright
hopeful2bright Dec. 5 at 12:24 AM
$ABUS
0 · Reply
Iightning
Iightning Dec. 4 at 11:17 PM
1ightning® Premium Options Alert (Actionable) Ticker: $ABUS Contract: Dec 19 $4C Entry: 0.47 Exit: 0.67 Return: +40.94% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 10:38 PM
Enter: $ABUS Calls Strike Price: $4 Expiry Date: JAN 16 2026 Buy in Price: $0.55 - $1.09 Sell Price: $1.85 Profit : +70% (Turn every $1 into $1.70) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Alfalcon
Alfalcon Dec. 4 at 10:20 PM
$ABUS ready to demote this slug to wagon status.
1 · Reply
FatedFish
FatedFish Dec. 4 at 9:06 PM
$ABUS
0 · Reply
NoBSPls
NoBSPls Dec. 4 at 7:30 PM
$ABUS I see 3 potential catalysts in the cards. 1. News on the pipeline. 2. B/O news 3. Progress on patent cases. Any/all could hit soon. This one requires steel nerves and a lot of patience. Another multi year journey for me 😊
1 · Reply
Blueviking
Blueviking Dec. 4 at 7:26 PM
$ABUS Been a cracy ass bus Wayne, what a ride🥳
0 · Reply
J_Wayne
J_Wayne Dec. 4 at 6:27 PM
$ABUS give me 10, 15, 20. Whatever….just want to get off the bus 😅
6 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 2:44 PM
$ABUS Share Price: $4.39 Contract Selected: Jun 18, 2026 $5 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.02 – $2.46 Potential Upside: 66% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
renoH4
renoH4 Dec. 4 at 1:24 PM
$ABUS ..adding, we are not far away of mother news.
1 · Reply
DocPharm
DocPharm Dec. 4 at 1:18 PM
$ABUS back from a long vacay … bonus points for whoever can tell me where R&R keeps you going - remember to take some self care here and there
8 · Reply
NakdEnergy
NakdEnergy Dec. 4 at 12:42 PM
$ABUS what’s going on?
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Dec. 4 at 12:40 PM
💎 LiquidTheta® Live Actionable Trade Asset: $ABUS Contracts: $ABUS January 15, 2027 $4 Calls Scale in: $2.31- $2.82 Scale out: $8.98-$15.39 Profit Potential : 311% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Blueviking
Blueviking Dec. 4 at 11:44 AM
$ABUS Hmmmmmmm
0 · Reply
Iightning
Iightning Dec. 4 at 6:57 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ABUS Contract: Dec 19 $3C Entry: 1.48 Exit: 2.11 Return: +43.24% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 6:57 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABUS $4.00 Put · DEC 19, 2025 Exp Entry Price: $0.25 - $0.35 Exit Price Target: $0.48 Profit Margin: +94% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Heavey
Heavey Dec. 4 at 12:08 AM
$ABUS 107k AH- nice
0 · Reply
Jdvm
Jdvm Dec. 3 at 11:12 PM
$ABUS over two million shares traded and were up.
1 · Reply
JB6791
JB6791 Dec. 3 at 8:54 PM
$ABUS tick tock $ROIV investor day coming up I have a feeling we get a share swap.
2 · Reply
Nile1
Nile1 Dec. 3 at 7:39 PM
$ABUS what was the news causing this run ?
2 · Reply
CapitalismUSA
CapitalismUSA Dec. 3 at 7:23 PM
$ABUS Will we get a settlement with Moderna in Jan-Feb? I can’t imagine they will let this go to trial in March. 🤞
1 · Reply
StockosaurusTex
StockosaurusTex Dec. 3 at 6:34 PM
$ABUS need more magic
1 · Reply